Clinical trials
Human Papillomavirus (HPV) clinical trials
Below are recruiting human papillomavirus (hpv) clinical trials, each written for real people, not researchers. We’re tracking 64 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07601074RecruitingPhase 2
Testing DARE-HPV to Clear Persistent HPV Infection
This study tests whether DARE-HPV, a new treatment, can help your body clear a persistent human papillomavirus (HPV) infection that hasn't gone away on its own. HPV is a common virus; persistent infection with certain high-risk types can lead to cervical cancer, so clearing it early may prevent future problems.
Phoenix, ArizonaAges 22–50 - NCT06434337Recruiting
HPV diagnostic test study
This study tests a new, quick diagnostic test for HPV (the virus that can cause cervical cancer). Researchers want to see if the test works well compared to regular tests. If you are due for an HPV test or a related procedure, this study may be a good fit.
Houston, TexasAges 21 years+ - NCT06995157Recruiting
HPV infections and vaccine attitudes in Slovenian women
This observational study looks at HPV infections and women's views about the HPV vaccine in Slovenia. It aims to understand the characteristics of HPV infections and attitudes toward vaccination after the vaccine became available.
Ljubljana, Municipality of DomžaleAges Up to 35 years - NCT07248904Recruiting
HPV education study for first-year nursing students
This study tests whether a special education program based on the transtheoretical model improves nursing students' knowledge about HPV, their health beliefs, and their intentions to get vaccinated. It aims to help students make informed decisions about HPV prevention.
Adana, CUKUROVAAges 18 years+ - NCT06198491Enrolling by invitation
HPV education study for women
This study tests how learning more about HPV affects women's beliefs about the virus. It may help you make informed health decisions.
Odunpazari, EskişehirAges 18 years+ - NCT07209917Recruiting
Cervical cancer prevention for women with HIV and HPV
This trial tests a new way to prevent cervical cancer in women with both HIV and HPV. It focuses on women in India who are already on stable HIV treatment and have a normal cervical exam.
Bangalore, KarnatakaAges 25–50 - NCT07281599Recruiting
Using a pad to screen for cervical precancer
This trial tests whether a special pad you wear during your period can detect signs of cervical precancer. If you are already scheduled for a colposcopy due to an abnormal Pap or HPV test, you might be able to participate.
New Haven, ConnecticutAges 25 years+ - NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT05334706RecruitingPhase 4
Vaccine study to lower HPV spread in HPV-positive women
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
L'Hospitalet de Llobregat, CataloniaAges 18 years+ - NCT05625633RecruitingPhase 2/Phase 3
HPV vaccine vs placebo for stubborn skin warts
This study tests whether an HPV vaccine can help shrink or clear cutaneous (skin) warts that have not responded to prior treatments. Participants get the study vaccine or a placebo to compare results and safety.
Salt Lake City, UtahAges 18 years+ - NCT05672927RecruitingPhase 4
Comparing HPV vaccine schedules: 2 doses vs 3 doses
This study compares how well your immune system responds to an HPV vaccine given as either 2 doses or 3 doses in people ages 27–45 who have never had the HPV vaccine. It may help improve HPV prevention strategies and guide the best dose schedule for adults.
Galveston, TexasAges 27–45 - NCT06574087Recruiting
Screening for anal cell changes in women with HPV related gynecological disease
This study looks at how often anal cell changes happen in women who have HPV-related gynecological problems. The goal is to find the best way to screen for these changes early.
Gdynia, Pomeranian VoivodeshipAges Any age - NCT06797986RecruitingPhase 1/Phase 2
Vaccine for HPV-positive head and neck cancer
This trial tests an investigational vaccine called BVAC-E6E7 for head and neck cancer caused by HPV types 16 or 18 that has come back or spread. It is for people who have already tried standard treatments like platinum chemo or immunotherapy, or can't take them.
SeoulAges 19 years+ - NCT06686043RecruitingPhase 2
HPV vaccine, imiquimod, and metformin for advanced cervical or vulvar cancer
This trial tests a combination of an HPV vaccine, an immune cream (imiquimod), and a diabetes drug (metformin) together with standard chemoradiation. The goal is to see if this mix helps treat advanced cervical, vaginal, or vulvar cancers better than standard care alone.
Houston, TexasAges 18–64 - NCT06793410RecruitingPhase 2
HPV vaccine after stem cell transplant
This trial tests if the HPV vaccine works safely in people who received a stem cell transplant from a donor. It may help prevent HPV-related cancers in transplant survivors.
Lund, Region SkåneAges 18–45 - NCT07275333Recruiting
HPV self-sampling for cervical screening in Ukraine
This trial tests if women can collect their own samples at home to check for HPV, a virus that can cause cervical cancer. It aims to make screening easier during the war in Ukraine.
ZaporizhzhyaAges 30–60 - NCT06942286Enrolling by invitation
HPV self-testing for cervical cancer screening in Indonesia
This study tests a home-based HPV self-collection kit for women who haven't been screened recently. The goal is to find cervical pre-cancer early, so treatment can prevent cancer.
Lebak, BantenAges 30–69 - NCT06624839RecruitingPhase 2
HPV vaccine study for people with and without HIV
This study tests how well the Gardasil 9 HPV vaccine works in people assigned male at birth, including those with HIV and those taking hormone therapy. Results could help protect against HPV-related cancers.
Washington D.C., District of ColumbiaAges 18–70 - NCT06129253Recruiting
GLOBE-HPV: Study of HPV in communities
This study is trying to find out how many people in different communities have HPV (human papillomavirus). It involves collecting samples and answering questions to help estimate the global burden of HPV.
DhakaAges 9–50 - NCT07209189RecruitingPhase 2
Chemo and immunotherapy before surgery for head and neck cancer
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
Baltimore, MarylandAges 18 years+ - NCT07214584Recruiting
Using blood and cervical tests to track cervical cancer treatment response
This trial checks how well cervical cancer responds to surgery, radiation, and chemotherapy by measuring HPV DNA and RNA in blood and cervical mucus. It aims to improve monitoring during treatment.
Gainesville, FloridaAges 18–89 - NCT07186530Enrolling by invitation
HPV self-collection for cervical cancer screening
This trial tests a new way for women to screen for cervical cancer by collecting their own sample for HPV testing at home or in a clinic. It aims to make screening easier for those who are overdue and may be anxious about a pelvic exam.
Rochester, MinnesotaAges 30–63 - NCT05985681RecruitingPhase 1
Vaccine to prevent HPV-related cancers
This trial tests a new vaccine (RG1-VLP) designed to prevent HPV-related cancers. It is for healthy women who have not been vaccinated against HPV before and are willing to receive three doses of the vaccine over several months.
Birmingham, AlabamaAges 18–60 - NCT07706673Enrolling by invitation
Long-term follow-up for HPV vaccine study participants
This study checks the long-term safety and effectiveness of the HPV vaccine (Gardasil 9) in people who received one or two doses in an earlier study. It aims to see how well the vaccine continues to protect against HPV-related conditions over many years.
Liberia, Guanacaste ProvinceAges 18 years+
Hear when a new Human Papillomavirus (HPV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for human papillomavirus (hpv)?
- Yes. Clin2 currently lists 64 recruiting human papillomavirus (hpv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a human papillomavirus (hpv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a human papillomavirus (hpv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.